A major advance in the molecular diagnosis of facioscapulohumeral muscular dystrophy is the recently reported elimination of confounding DNA fragments arising from homologous sequences located at lOq26. 
and also may prove useful for the diagnostic evaluation of apparently sporadic cases as they are more likely to have unambiguously small EcoRI/BlnI fragments.
In conclusion, these data clearly show that the Southern blot analysis with DNA probe p1 3E-11 using enzymes EcoRI and BlnI has greatly improved the molecular diagnostic test for FSHD. In FSHD patients with fragment sizes smaller than 35 kb, this test has a sensitivity approaching 95% while specificity approaches 100%. This represents a major step forward for both diagnostic confirmation as well as genetic counselling for those at risk of inheriting FSHD.
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